Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Wendy Ankrom, Ka Lai Yee, Rosa I. Sánchez, Adedayo Adedoyin, Fan Li, Thomas Marbury, Richard A. Preston, Marian Iwamoto, Sauzanne Khalilieh

Antimicrobial Agents and Chemotherapy · 2018 · 24 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

), respectively. Doravirine was generally well tolerated in both groups. Based on the overall efficacy, safety, and PK profile of doravirine, the minor effect of severe renal impairment on doravirine PK observed in this study is not considered clinically meaningful. (This study has been registered at ClinicalTrials.gov under identifier NCT02641067.).

References

19